Ozempic (semaglutide) is designed to slow digestion as part of its therapeutic effect. However, in some patients, this slowing appears to progress into severe gastrointestinal motility disorders, including digestive paralysis, bowel shutdown, and long-term inability to tolerate food.

As Ozempic prescriptions expanded beyond diabetes into weight loss, reports of serious motility-related injuries have increased, prompting legal scrutiny and inclusion of these injuries in federal GLP-1 litigation.

What Are Motility Disorders?

Motility disorders occur when the muscles and nerves of the digestive tract fail to move food properly, causing it to:

  • move extremely slowly
  • stop moving altogether
  • back up in the stomach or intestines

These conditions are functional, meaning they occur without a physical blockage.

Motility Disorders Reported in Ozempic Users

Reported conditions include:

  • gastroparesis (stomach paralysis)
  • ileus (functional bowel shutdown)
  • severe chronic constipation
  • intestinal dysmotility
  • generalized GI paralysis

Many patients require hospitalization.

Why Ozempic May Contribute to Motility Disorders

Ozempic works by:

  • delaying gastric emptying
  • suppressing appetite
  • altering gut-brain signaling

In some patients, this intended effect may become excessive or prolonged, especially with dose escalation or long-term use.

Symptoms That May Indicate a Serious Problem

Seek medical care if you experience:

  • persistent nausea or vomiting
  • inability to tolerate food
  • abdominal distension
  • constipation lasting days or weeks
  • severe abdominal pain
  • repeated dehydration

Diagnosis and Treatment

Diagnosis often involves:

  • gastric emptying studies
  • abdominal imaging
  • exclusion of mechanical obstruction
  • GI motility testing

Treatment options are limited and may not fully resolve symptoms.

Ozempic Motility Disorder Lawsuits

Ozempic lawsuits involving motility disorders typically allege:

  • inadequate warnings about severe digestive paralysis
  • under-disclosure of long-term GI risks
  • failure to identify high-risk patients

➡️ Related: Motility Disorders

Who May Qualify for a Claim Review

You may qualify if:

  • you used Ozempic, AND
  • you developed severe digestive dysfunction, AND
  • symptoms required hospitalization or persisted long-term

➡️ Start here: File a Claim

Severe motility disorders linked to Ozempic can cause long-lasting digestive disability and significant life disruption. These injuries are now a recognized category in GLP-1 litigation.